Surviving apoptosis

Andrew T M Vaughan, C. J. Betti, M. J. Villalobos

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The concept that cells subjected to chromatin cleavage during apoptosis are destined to die is being challenged. The execution phase of apoptosis is characterized by the activation of effector caspases, such as caspase-3, that cleave key regulatory or structural proteins and in particular activate apoptotic nucleases such as the caspase activated deoxyribonuclease (CAD). It is apparent that caspases of this type may become active both through non-apoptotic processing and potentially within cells that exhibit apoptotic morphology but are subsequently able to survive. In such systems caspase suppressor molecules, the inhibitors of apoptotic proteins or IAP's, may rescue cells from apoptotic nuclease(s) attack initiated by transient caspase activation. The MLL gene is involved in leukemogenic translocations in ALL and AML and is a target of nuclease cleavage during apoptosis. Translocations initiated at the site of apoptotic nuclease attack within MLL have been identified and may offer a model, with clinical relevance, for DNA damage mediated by the apoptosis system in cells destined to survive. The specificity of apoptotic cleavage combined with the potential for recovery from the execution phase of apoptosis suggests a novel and pathogenic role for apoptosis in creating translocations with leukemogenic potential.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalApoptosis
Volume7
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Apoptosis
Caspases
Chemical activation
Effector Caspases
Caspase 3
DNA Damage
Chromatin
Proteins
Genes
Recovery
Molecules
DNA
Processing

Keywords

  • Apoptosis
  • Caspase
  • IAP's
  • Leukemia
  • MLL
  • Translocations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

Vaughan, A. T. M., Betti, C. J., & Villalobos, M. J. (2002). Surviving apoptosis. Apoptosis, 7(2), 173-177. https://doi.org/10.1023/A:1014374717773

Surviving apoptosis. / Vaughan, Andrew T M; Betti, C. J.; Villalobos, M. J.

In: Apoptosis, Vol. 7, No. 2, 2002, p. 173-177.

Research output: Contribution to journalArticle

Vaughan, ATM, Betti, CJ & Villalobos, MJ 2002, 'Surviving apoptosis', Apoptosis, vol. 7, no. 2, pp. 173-177. https://doi.org/10.1023/A:1014374717773
Vaughan, Andrew T M ; Betti, C. J. ; Villalobos, M. J. / Surviving apoptosis. In: Apoptosis. 2002 ; Vol. 7, No. 2. pp. 173-177.
@article{d9e1afa2af6c4bd3b0603eb1294f4cd8,
title = "Surviving apoptosis",
abstract = "The concept that cells subjected to chromatin cleavage during apoptosis are destined to die is being challenged. The execution phase of apoptosis is characterized by the activation of effector caspases, such as caspase-3, that cleave key regulatory or structural proteins and in particular activate apoptotic nucleases such as the caspase activated deoxyribonuclease (CAD). It is apparent that caspases of this type may become active both through non-apoptotic processing and potentially within cells that exhibit apoptotic morphology but are subsequently able to survive. In such systems caspase suppressor molecules, the inhibitors of apoptotic proteins or IAP's, may rescue cells from apoptotic nuclease(s) attack initiated by transient caspase activation. The MLL gene is involved in leukemogenic translocations in ALL and AML and is a target of nuclease cleavage during apoptosis. Translocations initiated at the site of apoptotic nuclease attack within MLL have been identified and may offer a model, with clinical relevance, for DNA damage mediated by the apoptosis system in cells destined to survive. The specificity of apoptotic cleavage combined with the potential for recovery from the execution phase of apoptosis suggests a novel and pathogenic role for apoptosis in creating translocations with leukemogenic potential.",
keywords = "Apoptosis, Caspase, IAP's, Leukemia, MLL, Translocations",
author = "Vaughan, {Andrew T M} and Betti, {C. J.} and Villalobos, {M. J.}",
year = "2002",
doi = "10.1023/A:1014374717773",
language = "English (US)",
volume = "7",
pages = "173--177",
journal = "Apoptosis : an international journal on programmed cell death",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Surviving apoptosis

AU - Vaughan, Andrew T M

AU - Betti, C. J.

AU - Villalobos, M. J.

PY - 2002

Y1 - 2002

N2 - The concept that cells subjected to chromatin cleavage during apoptosis are destined to die is being challenged. The execution phase of apoptosis is characterized by the activation of effector caspases, such as caspase-3, that cleave key regulatory or structural proteins and in particular activate apoptotic nucleases such as the caspase activated deoxyribonuclease (CAD). It is apparent that caspases of this type may become active both through non-apoptotic processing and potentially within cells that exhibit apoptotic morphology but are subsequently able to survive. In such systems caspase suppressor molecules, the inhibitors of apoptotic proteins or IAP's, may rescue cells from apoptotic nuclease(s) attack initiated by transient caspase activation. The MLL gene is involved in leukemogenic translocations in ALL and AML and is a target of nuclease cleavage during apoptosis. Translocations initiated at the site of apoptotic nuclease attack within MLL have been identified and may offer a model, with clinical relevance, for DNA damage mediated by the apoptosis system in cells destined to survive. The specificity of apoptotic cleavage combined with the potential for recovery from the execution phase of apoptosis suggests a novel and pathogenic role for apoptosis in creating translocations with leukemogenic potential.

AB - The concept that cells subjected to chromatin cleavage during apoptosis are destined to die is being challenged. The execution phase of apoptosis is characterized by the activation of effector caspases, such as caspase-3, that cleave key regulatory or structural proteins and in particular activate apoptotic nucleases such as the caspase activated deoxyribonuclease (CAD). It is apparent that caspases of this type may become active both through non-apoptotic processing and potentially within cells that exhibit apoptotic morphology but are subsequently able to survive. In such systems caspase suppressor molecules, the inhibitors of apoptotic proteins or IAP's, may rescue cells from apoptotic nuclease(s) attack initiated by transient caspase activation. The MLL gene is involved in leukemogenic translocations in ALL and AML and is a target of nuclease cleavage during apoptosis. Translocations initiated at the site of apoptotic nuclease attack within MLL have been identified and may offer a model, with clinical relevance, for DNA damage mediated by the apoptosis system in cells destined to survive. The specificity of apoptotic cleavage combined with the potential for recovery from the execution phase of apoptosis suggests a novel and pathogenic role for apoptosis in creating translocations with leukemogenic potential.

KW - Apoptosis

KW - Caspase

KW - IAP's

KW - Leukemia

KW - MLL

KW - Translocations

UR - http://www.scopus.com/inward/record.url?scp=0036211060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036211060&partnerID=8YFLogxK

U2 - 10.1023/A:1014374717773

DO - 10.1023/A:1014374717773

M3 - Article

C2 - 11865202

AN - SCOPUS:0036211060

VL - 7

SP - 173

EP - 177

JO - Apoptosis : an international journal on programmed cell death

JF - Apoptosis : an international journal on programmed cell death

SN - 1360-8185

IS - 2

ER -